OPTN ||| S:0 E:4 ||| NNP
/ ||| S:4 E:5 ||| NNP
SRTR  ||| S:5 E:10 ||| NNP
2011  ||| S:10 E:15 ||| CD
Annual  ||| S:15 E:22 ||| NNP
Data  ||| S:22 E:27 ||| NNP
Report ||| S:27 E:33 ||| NNP
:  ||| S:33 E:35 ||| :
kidney  ||| S:35 E:42 ||| VBG
A  ||| S:42 E:44 ||| DT
shortage  ||| S:44 E:53 ||| NN
of  ||| S:53 E:56 ||| IN
kidneys  ||| S:56 E:64 ||| NN
for  ||| S:64 E:68 ||| IN
transplant  ||| S:68 E:79 ||| NN
remains  ||| S:79 E:87 ||| VBZ
a  ||| S:87 E:89 ||| DT
major  ||| S:89 E:95 ||| JJ
problem  ||| S:95 E:103 ||| NN
for  ||| S:103 E:107 ||| IN
patients  ||| S:107 E:116 ||| NNS
with  ||| S:116 E:121 ||| IN
end-stage  ||| S:121 E:131 ||| JJ
renal  ||| S:131 E:137 ||| JJ
disease ||| S:137 E:144 ||| NN
.  ||| S:144 E:146 ||| .
The  ||| S:146 E:150 ||| DT
number  ||| S:150 E:157 ||| NN
of  ||| S:157 E:160 ||| IN
candidates  ||| S:160 E:171 ||| NNS
on  ||| S:171 E:174 ||| IN
the  ||| S:174 E:178 ||| DT
waiting  ||| S:178 E:186 ||| VBG
list  ||| S:186 E:191 ||| NN
continues  ||| S:191 E:201 ||| VBZ
to  ||| S:201 E:204 ||| TO
increase  ||| S:204 E:213 ||| VB
each  ||| S:213 E:218 ||| DT
year ||| S:218 E:222 ||| NN
,  ||| S:222 E:224 ||| ,
while  ||| S:224 E:230 ||| IN
organ  ||| S:230 E:236 ||| JJ
donation  ||| S:236 E:245 ||| NN
numbers  ||| S:245 E:253 ||| NNS
remain  ||| S:253 E:260 ||| VBP
flat ||| S:260 E:264 ||| JJ
.  ||| S:264 E:266 ||| .
Thus ||| S:266 E:270 ||| RB
,  ||| S:270 E:272 ||| ,
transplant  ||| S:272 E:283 ||| NN
rates  ||| S:283 E:289 ||| NNS
for  ||| S:289 E:293 ||| IN
adult  ||| S:293 E:299 ||| JJ
wait-listed  ||| S:299 E:311 ||| JJ
candidates  ||| S:311 E:322 ||| NNS
continue  ||| S:322 E:331 ||| VBP
to  ||| S:331 E:334 ||| TO
decrease ||| S:334 E:342 ||| VB
.  ||| S:342 E:344 ||| .
However ||| S:344 E:351 ||| RB
,  ||| S:351 E:353 ||| ,
pretransplant  ||| S:353 E:367 ||| JJ
mortality  ||| S:367 E:377 ||| NN
rates  ||| S:377 E:383 ||| NNS
also  ||| S:383 E:388 ||| RB
show  ||| S:388 E:393 ||| VB
a  ||| S:393 E:395 ||| DT
decreasing  ||| S:395 E:406 ||| JJ
trend ||| S:406 E:411 ||| NN
.  ||| S:411 E:413 ||| .
Many  ||| S:413 E:418 ||| JJ
kidneys  ||| S:418 E:426 ||| NN
recovered  ||| S:426 E:436 ||| VBD
for  ||| S:436 E:440 ||| IN
transplant  ||| S:440 E:451 ||| NNS
are  ||| S:451 E:455 ||| VBP
discarded ||| S:455 E:464 ||| VBN
,  ||| S:464 E:466 ||| ,
and  ||| S:466 E:470 ||| CC
discard  ||| S:470 E:478 ||| JJ
rates  ||| S:478 E:484 ||| NNS
are  ||| S:484 E:488 ||| VBP
increasing ||| S:488 E:498 ||| VBG
.  ||| S:498 E:500 ||| .
Living  ||| S:500 E:507 ||| VBG
donation  ||| S:507 E:516 ||| JJ
rates  ||| S:516 E:522 ||| NNS
have  ||| S:522 E:527 ||| VBP
been  ||| S:527 E:532 ||| VBN
essentially  ||| S:532 E:544 ||| RB
unchanged  ||| S:544 E:554 ||| JJ
for  ||| S:554 E:558 ||| IN
the  ||| S:558 E:562 ||| DT
past  ||| S:562 E:567 ||| JJ
decade ||| S:567 E:573 ||| NN
,  ||| S:573 E:575 ||| ,
despite  ||| S:575 E:583 ||| IN
introduction  ||| S:583 E:596 ||| NN
of  ||| S:596 E:599 ||| IN
desensitization ||| S:599 E:614 ||| NN
,  ||| S:614 E:616 ||| ,
non-directed  ||| S:616 E:629 ||| JJ
donations ||| S:629 E:638 ||| NNS
,  ||| S:638 E:640 ||| ,
and  ||| S:640 E:644 ||| CC
kidney  ||| S:644 E:651 ||| NN
paired  ||| S:651 E:658 ||| VBN
donation  ||| S:658 E:667 ||| JJ
programs ||| S:667 E:675 ||| NNS
.  ||| S:675 E:677 ||| .
For  ||| S:677 E:681 ||| IN
both  ||| S:681 E:686 ||| DT
living  ||| S:686 E:693 ||| NN
and  ||| S:693 E:697 ||| CC
deceased  ||| S:697 E:706 ||| JJ
donor  ||| S:706 E:712 ||| NN
recipients ||| S:712 E:722 ||| NNS
,  ||| S:722 E:724 ||| ,
early  ||| S:724 E:730 ||| RB
posttransplant  ||| S:730 E:745 ||| JJ
results  ||| S:745 E:753 ||| NNS
have  ||| S:753 E:758 ||| VBP
shown  ||| S:758 E:764 ||| VBN
ongoing  ||| S:764 E:772 ||| JJ
improvement ||| S:772 E:783 ||| NN
,  ||| S:783 E:785 ||| ,
driven  ||| S:785 E:792 ||| VBN
by  ||| S:792 E:795 ||| IN
decreases  ||| S:795 E:805 ||| NNS
in  ||| S:805 E:808 ||| IN
rates  ||| S:808 E:814 ||| NNS
of  ||| S:814 E:817 ||| IN
graft  ||| S:817 E:823 ||| JJ
failure  ||| S:823 E:831 ||| NN
and  ||| S:831 E:835 ||| CC
return  ||| S:835 E:842 ||| NN
to  ||| S:842 E:845 ||| TO
dialysis ||| S:845 E:853 ||| NN
.  ||| S:853 E:855 ||| .
Immunosuppressive  ||| S:855 E:873 ||| JJ
drug  ||| S:873 E:878 ||| NN
use  ||| S:878 E:882 ||| NN
has  ||| S:882 E:886 ||| VBZ
changed  ||| S:886 E:894 ||| VBN
little ||| S:894 E:900 ||| RB
,  ||| S:900 E:902 ||| ,
except  ||| S:902 E:909 ||| IN
for  ||| S:909 E:913 ||| IN
the  ||| S:913 E:917 ||| DT
Food  ||| S:917 E:922 ||| NNP
and  ||| S:922 E:926 ||| CC
Drug  ||| S:926 E:931 ||| NNP
Administration  ||| S:931 E:946 ||| NNP
approval  ||| S:946 E:955 ||| NN
of  ||| S:955 E:958 ||| IN
belatacept  ||| S:958 E:969 ||| NN
in  ||| S:969 E:972 ||| IN
2011 ||| S:972 E:976 ||| CD
,  ||| S:976 E:978 ||| ,
the  ||| S:978 E:982 ||| DT
first  ||| S:982 E:988 ||| JJ
approval  ||| S:988 E:997 ||| NN
of  ||| S:997 E:1000 ||| IN
a  ||| S:1000 E:1002 ||| DT
maintenance  ||| S:1002 E:1014 ||| NN
immunosuppressive  ||| S:1014 E:1032 ||| NN
drug  ||| S:1032 E:1037 ||| NN
in  ||| S:1037 E:1040 ||| IN
more  ||| S:1040 E:1045 ||| JJR
than  ||| S:1045 E:1050 ||| IN
a  ||| S:1050 E:1052 ||| DT
decade ||| S:1052 E:1058 ||| NN
.  ||| S:1058 E:1060 ||| .
Pediatric  ||| S:1060 E:1070 ||| JJ
kidney  ||| S:1070 E:1077 ||| NN
transplant  ||| S:1077 E:1088 ||| NN
candidates  ||| S:1088 E:1099 ||| NNS
receive  ||| S:1099 E:1107 ||| VBP
priority  ||| S:1107 E:1116 ||| NN
under  ||| S:1116 E:1122 ||| IN
the  ||| S:1122 E:1126 ||| DT
Share  ||| S:1126 E:1132 ||| NN
35  ||| S:1132 E:1135 ||| CD
policy ||| S:1135 E:1141 ||| NN
.  ||| S:1141 E:1143 ||| .
The  ||| S:1143 E:1147 ||| DT
number  ||| S:1147 E:1154 ||| NN
of  ||| S:1154 E:1157 ||| IN
pediatric  ||| S:1157 E:1167 ||| JJ
transplants  ||| S:1167 E:1179 ||| NNS
peaked  ||| S:1179 E:1186 ||| VBN
in  ||| S:1186 E:1189 ||| IN
2005 ||| S:1189 E:1193 ||| CD
,  ||| S:1193 E:1195 ||| ,
and  ||| S:1195 E:1199 ||| CC
decreased  ||| S:1199 E:1209 ||| VBD
to  ||| S:1209 E:1212 ||| TO
a  ||| S:1212 E:1214 ||| DT
low  ||| S:1214 E:1218 ||| JJ
of  ||| S:1218 E:1221 ||| IN
760  ||| S:1221 E:1225 ||| CD
in  ||| S:1225 E:1228 ||| IN
2011 ||| S:1228 E:1232 ||| CD
.  ||| S:1232 E:1234 ||| .
Graft  ||| S:1234 E:1240 ||| JJ
survival  ||| S:1240 E:1249 ||| NN
and  ||| S:1249 E:1253 ||| CC
short-term  ||| S:1253 E:1264 ||| JJ
renal  ||| S:1264 E:1270 ||| JJ
function  ||| S:1270 E:1279 ||| NNS
continue  ||| S:1279 E:1288 ||| VBP
to  ||| S:1288 E:1291 ||| TO
improve  ||| S:1291 E:1299 ||| VB
for  ||| S:1299 E:1303 ||| IN
pediatric  ||| S:1303 E:1313 ||| JJ
recipients ||| S:1313 E:1323 ||| NNS
.  ||| S:1323 E:1325 ||| .
Postransplant  ||| S:1325 E:1339 ||| JJ
lymphoproliferative  ||| S:1339 E:1359 ||| JJ
disorder  ||| S:1359 E:1368 ||| NN
is  ||| S:1368 E:1371 ||| VBZ
an  ||| S:1371 E:1374 ||| DT
important  ||| S:1374 E:1384 ||| JJ
concern ||| S:1384 E:1391 ||| NN
,  ||| S:1391 E:1393 ||| ,
occurring  ||| S:1393 E:1403 ||| VBG
in  ||| S:1403 E:1406 ||| RP
about  ||| S:1406 E:1412 ||| IN
one-third  ||| S:1412 E:1422 ||| NN
of  ||| S:1422 E:1425 ||| IN
pediatric  ||| S:1425 E:1435 ||| JJ
recipients ||| S:1435 E:1445 ||| NNS
.  ||| S:1445 E:1447 ||| .
